X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (169) 169
Publication (21) 21
Book Chapter (6) 6
Conference Proceeding (2) 2
Streaming Video (2) 2
Web Resource (2) 2
Book Review (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (60) 60
index medicus (57) 57
hematology (43) 43
oncology (37) 37
female (32) 32
middle aged (32) 32
male (30) 30
adult (27) 27
lymphomas (25) 25
aged (24) 24
treatment outcome (24) 24
hematology, oncology and palliative medicine (23) 23
transplantation (21) 21
cancer (20) 20
chemotherapy (20) 20
rituximab (20) 20
article (18) 18
disease-free survival (17) 17
antineoplastic combined chemotherapy protocols - therapeutic use (15) 15
survival (15) 15
aged, 80 and over (14) 14
lymphoma (14) 14
young adult (14) 14
analysis (12) 12
hemic and lymphatic diseases (12) 12
non-hodgkins-lymphoma (12) 12
recurrence (12) 12
immunology (11) 11
prognosis (11) 11
retrospective studies (11) 11
transplantation, homologous (11) 11
care and treatment (10) 10
hematopoietic stem cell transplantation - methods (10) 10
leukemia (10) 10
neoplasm staging (10) 10
drug therapy (9) 9
expression (9) 9
immune system diseases (9) 9
lymphoma, large b-cell, diffuse - drug therapy (9) 9
survival rate (9) 9
transplantation, autologous (9) 9
hematopoietic stem cell transplantation (8) 8
hematopoietic stem cells (8) 8
immunotherapy (8) 8
lymphoma, large b-cell, diffuse - genetics (8) 8
lymphoma, large b-cell, diffuse - mortality (8) 8
non-hodgkin lymphoma (8) 8
patients (8) 8
survival analysis (8) 8
therapy (8) 8
abridged index medicus (7) 7
b-cell lymphoma (7) 7
chronic lymphocytic-leukemia (7) 7
combined modality therapy (7) 7
elderly-patients (7) 7
lymphoma, large b-cell, diffuse - therapy (7) 7
multicenter (7) 7
rituximab plus cyclophosphamide (7) 7
adolescent (6) 6
antineoplastic agents (6) 6
antineoplastic agents - administration & dosage (6) 6
diffuse large b-cell lymphoma (6) 6
hodgkin lymphoma (6) 6
impact (6) 6
lymphoma, large b-cell, diffuse - pathology (6) 6
myc (6) 6
neoplasms (6) 6
phase-ii (6) 6
phase-ii trial (6) 6
poor-prognosis (6) 6
progression-free survival (6) 6
risk (6) 6
stem cell transplantation (6) 6
transplantation conditioning - methods (6) 6
antibodies, monoclonal, murine-derived - administration & dosage (5) 5
antineoplastic agents - therapeutic use (5) 5
antineoplastic combined chemotherapy protocols - administration & dosage (5) 5
autologous transplantation (5) 5
bcl2 (5) 5
cyclophosphamide - therapeutic use (5) 5
disease (5) 5
doxorubicin (5) 5
doxorubicin - therapeutic use (5) 5
gene (5) 5
high-dose chemotherapy (5) 5
high-dose therapy (5) 5
lenalidomide (5) 5
leukemia, lymphocytic, chronic, b-cell - therapy (5) 5
multiple-myeloma (5) 5
non-hodgkin-lymphoma (5) 5
open-label (5) 5
outcomes (5) 5
precision medicine (5) 5
prednisone - therapeutic use (5) 5
r-chop (5) 5
radioimmunotherapy (5) 5
stem-cell transplantation (5) 5
t cells (5) 5
thalidomide - analogs & derivatives (5) 5
trial (5) 5
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 07/2014, Volume 371, Issue 3, pp. 213 - 223
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 10/2019, Volume 74, Issue 13, pp. 1667 - 1678
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. e17046 - e17046
Journal Article
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 4100 - 4100
Background: Ten to 15% of diffuse large B cell lymphoma (DLBCL) patients exhibit primary refractory disease (nonresponse or relapse within 3 months of therapy)... 
Journal Article
British Journal of Haematology, ISSN 0007-1048, 02/2018, Volume 180, Issue 4, pp. 534 - 544
Summary Primary mediastinal (thymic) large B‐cell lymphoma (PMBCL) is an uncommon subtype of non‐Hodgkin lymphoma (NHL) that presents with a mediastinal mass... 
PMBCL | non‐Hodgkin lymphoma | chemotherapy | non-Hodgkin lymphoma | SURVIVAL | SINGLE INSTITUTION | CYCLOPHOSPHAMIDE | DOXORUBICIN | THERAPY | RITUXIMAB | VINCRISTINE | PROGNOSTIC-SIGNIFICANCE | RADIOTHERAPY | HEMATOLOGY | Doxorubicin - therapeutic use | Recurrence | Humans | Lymphoma, B-Cell - diagnosis | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Mediastinal Neoplasms - mortality | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Young Adult | Mediastinal Neoplasms - drug therapy | Neoplasm Grading | Treatment Failure | Adult | Female | Retrospective Studies | Lymphoma, B-Cell - drug therapy | Etoposide - adverse effects | Lymphoma, B-Cell - mortality | Prednisone - adverse effects | Etoposide - therapeutic use | Treatment Outcome | Combined Modality Therapy | Mediastinal Neoplasms - diagnosis | Rituximab - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Disease Management | Neoplasm Staging | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Anthracyclines | Cyclophosphamide | Chemotherapy | Corticosteroids | Analysis | Lymphomas | Prednisone | Cancer | Toxicity | Complications | Radiation | Rituximab | Etoposide | Lymphoma | Patients | Survival | Doxorubicin | Vincristine | Thymus | Demographics | Historical account | Lymphocytes B | B-cell lymphoma
Journal Article
Journal Article
British Journal of Haematology, ISSN 0007-1048, 11/2016, Volume 175, Issue 4, pp. 631 - 640
Summary Rearrangement of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma (DLBCL) and B cell lymphoma unclassifiable... 
fluorescence in situ hybridization | B cell lymphoma unclassifiable | diffuse large B cell lymphoma | chemotherapy | MYC | SURVIVAL | TRANSLOCATION | IMMUNOCHEMOTHERAPY | R-CHOP | CLASSIFICATION | TRANSPLANTATION | IMPACT | fluorescence insitu hybridization | BURKITT-LYMPHOMA | FEATURES INTERMEDIATE | HEMATOLOGY | EXPRESSION | Doxorubicin - therapeutic use | Prognosis | Humans | Lymphoma, B-Cell - diagnosis | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Genes, myc | Lymphoma, B-Cell - genetics | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Adult | Female | Lymphoma, B-Cell - drug therapy | Lymphoma, B-Cell - mortality | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Proportional Hazards Models | Treatment Outcome | Lymphoma, Large B-Cell, Diffuse - mortality | Lymphoma, Large B-Cell, Diffuse - diagnosis | Gene Amplification | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bone Marrow - pathology | Gene Rearrangement | Vincristine - therapeutic use | Biomarkers | Vincristine - adverse effects | Aged | Neoplasm Staging | Antibodies, Monoclonal, Murine-Derived - adverse effects | Lymphoma, Large B-Cell, Diffuse - genetics | Doxorubicin - adverse effects | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Lymphomas | Gene amplification | B cell lymphoma | CHEMOTHERAPY | Gene rearrangement
Journal Article
Leukemia and Lymphoma, ISSN 1042-8194, 05/2018, Volume 60, Issue 1, pp. 1 - 13
Primary central nervous lymphoma (PCNSL) is a rare extra-nodal subtype of non-Hodgkin lymphoma and most cases are of diffuse large B-cell lymphoma histology... 
frontline | approach | PCNSL | PRIMARY CNS LYMPHOMA | COGNITIVE FUNCTIONS | 1ST-LINE TREATMENT | HIGH-DOSE METHOTREXATE | PHASE-II | WHOLE-BRAIN RADIOTHERAPY | RADIATION-THERAPY | ONCOLOGY | NON-HODGKINS-LYMPHOMA | STEM-CELL TRANSPLANTATION | HEMATOLOGY | EPSTEIN-BARR-VIRUS
Journal Article
Journal of Oncology Pharmacy Practice, ISSN 1078-1552, 12/2019, Volume 25, Issue 8, pp. 1927 - 1932
Background Androgen deprivation therapy (ADT) remains a standard of care in metastatic prostate cancer. Recent prospective trials have explored addition of... 
Deprivation | Urban areas | Hazard identification | Radiation | Clinical trials | Metastasis | Regression analysis | Cancer therapies | Survival | Data bases | Subgroups | Urban environments | Metastases | Quality of life | Survival analysis | Androgens | Chemotherapy | Databases | Prostate cancer | Prostate | Age | Cancer
Journal Article
American Journal of Hematology, ISSN 0361-8609, 12/2019, Volume 94, Issue 12, pp. 1353 - 1363
Ibrutinib, a once‐daily oral inhibitor of Bruton's tyrosine kinase, is approved in the United States and Europe for treatment of patients with chronic... 
Journal Article